| List | Section | Observation |
|---|---|---|
| Bolivia | LINAME 2011 - 2013 | No observations |
| List | Section | Observation |
|---|---|---|
| Peru | 8.2 Cytotoxics | No observations |
| List | Section | Observation |
|---|---|---|
| Peru | 8.2 Cytotoxics | No observations |
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 8.2.3 Immunomodulators |
Others observations: Including quality-assured biosimilars. − Primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy. − Secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy − To facilitate administration of dose dense chemotherapy regimens |